The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, registering a compound annual growth rate (CAGR) of 5.8% during the forecast period from 2022 to 2030. 

Amyotrophic lateral sclerosis (ALS) is also known as amyotrophic lateral sclerosis. It is a degenerative nervous system illness that affects nerve cells in the brain and spinal cord, thereby resulting in muscular control loss.

Factors Influencing the Market

Due to the growing prevalence of amyotrophic lateral sclerosis disease, the global amyotrophic lateral sclerosis treatment market will grow during the study period. Centers for Disease Control and Prevention (CDC) estimates around 14,500 to 15,000 people in the U.S. had amyotrophic lateral sclerosis in 2016. Moreover, the same source estimates that approximately 2 to 5 people in every 100,000 are suffering from amyotrophic lateral sclerosis. Thus, the growing prevalence of the disease is likely to boost the market growth. 

The growing geriatric population is forecast to propel the growth of the amyotrophic lateral sclerosis treatment market. On the contrary, the high cost of treatment may hamper the market during the study period.

The increasing healthcare expenditure and growing consumer awareness about the treatment may surge the growth of the market. 

Regional Analysis

North America is forecast to dominate the global market for amyotrophic lateral sclerosis treatments. Due to the increasing number of patients with amyotrophic lateral sclerosis, North America is forecast to lead in the global market over the projection period. Additionally, commercial and public entities collaborate and partner strategically to improve outcomes in the treatment of amyotrophic lateral sclerosis in the region. Moreover, the high health expenditure of the countries and favorable government initiatives are forecast to boost the market growth during the study period. 

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, the focus on other diseases declined rapidly. Healthcare bodies were more focused on controlling the rapidly growing infections. Thus, the global amyotrophic lateral sclerosis treatment market witnessed significant disruptions. However, the focus of government bodies has been increasing toward the healthcare segment. Thus, the market may witness favorable opportunities in the coming years. Moreover, amyotrophic lateral sclerosis disease is growing rapidly and so is the demand for effective treatment. Thus, the market will witness ample growth opportunities in the coming years. 

Market Segmentation

The global amyotrophic lateral sclerosis treatment market segmentation focuses on Drug, Treatment, End-User, and Region. 

Drug Type

• Sporadic ALS (SALS)
• Familial ALS (FALS)

Treatment Type

• Medication
• Physical Therapy
• Respiratory Therapy
• Speech Therapy
• Others

End-Users

• Hospitals
• Specialty Centres
• Research & Academic Institutes
• Others

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America

Competitors in the Market

• Mitsubishi Tanabe Pharma Corporation
• Otsuka Pharmaceutical Co., Ltd.
• BrainStorm Therapeutics
• Biogen Inc.
• Corestem
• AB Science
• F.Hoffmann-La Roche AG
• Biohaven Pharmaceutical
• Sun Pharmaceutical
• Ionis Pharmaceuticals, Inc.
• Other prominent players